Optimizing Pharmacokinetics and Pharmacodynamics of Intravenous Amikacin in Cystic Fibrosis Patients: Assessment of Clinical Outcomes and Nephrotoxicity

Update Item Information
Identifier 067_Huynh-Hoa_EBPF2017
Title Optimizing Pharmacokinetics and Pharmacodynamics of Intravenous Amikacin in Cystic Fibrosis Patients: Assessment of Clinical Outcomes and Nephrotoxicity
Creator Huynh, Hoa Q.; Illamola, Silvia M.; Liu, Xiaoxi; Bhakta, Zubin; Liou, Theodore; Carveth, Holly; Young, David C.
Subject Evidence-Based Practice; Genes, Regulator; Cystic Fibrosis; Amikacin; Administration, Intravenous; Pharmacokinetics; Treatment Outcome; Poster
Description Cystic fibrosis is a recessive genetic disorder caused by a mutation in the cystic fibrosis transmembrane regulator gene. The mutation results in the inability to regulate chloride channels on epithelial cells, leading to inflammation, obstruction, and infection of the pulmonary tract. Declining lung function results in episodes of acute pulmonary exacerbation requiring antibiotic and airway clearance treatments. Amikacin has been used in patients who do not tolerate or are resistant to tobramycin. Amikacin is the primary aminoglycoside used for the treatment of non- tuberculosis mycobacterium. Optimal dosing regimen for amikacin remains unclear. Determine the optimal amikacin dosing regimens in cystic fibrosis patients with an acute pulmonary exacerbation. Develop a Monte Carlo simulation for amikacin dosing. Optimizing amikacin dosing to increase positive clinical outcomes and reduce nephrotoxicity.
Relation is Part of Evidence Based Practice Posters - 2017
Publisher Spencer S. Eccles Health Sciences Library, University of Utah
Date Digital 2017
Date 2017
Type Text
Format application/pdf
Language eng
ARK ark:/87278/s6rj8wz6
Setname ehsl_ebp
ID 1399436
Reference URL https://collections.lib.utah.edu/ark:/87278/s6rj8wz6
Back to Search Results